NASDAQ · SHOTU
RMG ML Sports Holdings
$10.08$0.00 (0.0%)
RMG ML Sports Holdings’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
Loading market information…
NASDAQ · DRRX · USD
Stock price, earnings
Quote as of Sep 11, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
DURECT Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow DURECT Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
DURECT Corporation is a biopharmaceutical enterprise dedicated to the research and development of innovative medicines, leveraging its epigenetic regulator and pharmaceutical platforms. The company provides the ALZET product range, which includes osmotic pumps and associated accessories vital for research studies conducted on mice, rats, and other laboratory animals. In its development pipeline, DURECT is advancing larsucosterol (DUR-928), an endogenous, orally administered small molecule. This compound, currently undergoing a Phase IIb clinical trial for alcohol-associated hepatitis, is designed to regulate lipid metabolism, stress and inflammatory pathways, and cellular survival and death. A Phase Ib clinical trial for patients with nonalcoholic steatohepatitis has also been successfully completed. Additionally, DURECT markets POSIMIR, a product aimed at managing post-surgical pain in adults by delivering bupivacaine for an extended period. The company also offers Methydur, a treatment for attention deficit hyperactivity disorder. Sales of the ALZET product line are managed by an in-house sales force across the United States and through an extensive network of distributors internationally, including Japan and Europe. DURECT Corporation engages in strategic collaborations and agreements with various partners, such as the Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Santen Pharmaceutical Co., Ltd. Established in 1998, DURECT Corporation maintains its headquarters in Cupertino, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 27, 2024 | -$0.10+72.22% vs estimate | $2.67M+7.57% vs estimate |
|---|
| Q3 2023 | Nov 13, 2023 | -$0.14+65.85% vs estimate | $1.74M-28.82% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.08$0.00 (0.0%)
RMG ML Sports Holdings’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
$9.15$0.00 (-0.22%)
Chicago Atlantic BDC, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.81% below the high.
$1.30+$0.03 (+2.36%)
Zynerba Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.14% below the high.
$0.76$0.00 (0.0%)
The Valens Company Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
$2.38+$0.01 (+0.42%)
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
